EVMN
INSIDER BUYEvommune, Inc.
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
NegativeEvommune experienced a significant pipeline setback in June 2026 when EVO756 failed its Phase 2b trial in chronic spontaneous urticaria, triggering multiple analyst downgrades and a strategic pivot away from the CSU indication. However, positive Phase 2a data for lead asset EVO301 in atopic dermatitis (announced September-October 2026) partially restored investor confidence, though the company now depends heavily on EVO301's continued success following the loss of its secondary pipeline asset.
Red flags
- •EVO756 Phase 2b trial failure in CSU—missed primary endpoint, eliminating major pipeline asset and market opportunity
- •Multiple analyst downgrades following trial failure (William Blair to Market Perform, Raymond James cut from Strong Buy to Outperform with price target cut from $52 to $32)
- •Significant stock decline from ~$27.88 (private placement price in Feb 2026) to ~$17.16 by late June—38% drawdown post-failure
- •Increased pipeline concentration risk: company now heavily dependent on single lead asset (EVO301) after losing EVO756 indication
- •Strategic pivot required post-failure indicates need for course correction and suggests earlier investment thesis was partially invalidated
Insider Activity
Fund 13D/13G Filings (1)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).